Cavanagh Bethany J 4

What Happened
Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (BEAM), sold 3,034 shares of common stock on 2026-01-20 at $30.12 per share, generating proceeds of $91,384. This was a sale (not a purchase) and therefore is generally considered routine insider selling rather than a bullish purchase.

Key Details

• Transaction date and price: 2026-01-20, 3,034 shares at $30.12 each (total $91,384). Transaction code: S (Sale).
• Manner: Reported as an open-market or private sale.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: The sale was made pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on September 19, 2025.
• Filing timeliness: Report filed 2026-01-21 for a 2026-01-20 transaction — appears to be filed within the normal Form 4 reporting window.

Context
Sales under Rule 10b5‑1 plans are prearranged and often reflect scheduled, automated dispositions rather than a contemporaneous view of the company’s prospects. For retail investors, purchases typically carry more direct informational value than routine sales; a single planned sale like this should be viewed as one data point among many when assessing insider sentiment.